Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Evaluating the benefits of selective CDK4 inhibition in HR+/HER2- breast cancer

Antonio Giordano, MD, PhD, Dana Farber Cancer Institute, Boston, MA, comments on the potential advantages of PF-07220060, a selective CDK4 inhibitor, in patients with HR+/HER2- breast cancer. Specifically targeting CDK4 can increase cell cycle inhibition in cancer, reducing toxicity and adverse events such as neutropenia, thrombocytopenia, nausea and vomiting. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.